<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 6, 1998
DEPOMED, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 001-13111 94-3229046
- -------------------------------------------------------------------------------
(State of Incorporation (Commission File Number) (I.R.S. Employer
or Organization) Identification No.)
366 Lakeside Drive, Foster City, California 94404
- ------------------------------------------------------ ---------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone no., including area code: (650) 513-0990
--------------
NOT APPLICABLE
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
On November 6, 1998, DepoMed, Inc. issued a press release announcing that
its common stock and warrants had been approved for listing on the American
Stock Exchange. The press release is attached hereto as Exhibit 99.1.
The Exhibit hereto is incorporated by reference herein and forms an
integral part hereof.
Item 7. Financial Statements and Exhibits.
Exhibits.
99.1 Press Release dated November 6, 1998.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: November 9, 1998
DEPOMED, INC.
/s/ John F. Hamilton
------------------------
John F. Hamilton
Vice President - Finance and
Chief Financial Officer
<PAGE>
EXHIBIT INDEX
Exhibit
99.1 Press Release dated November 6, 1998.
<PAGE>
EXHIBIT 99.1
DEPOMED, INC. LISTS ON THE AMERICAN STOCK EXCHANGE
FOSTER CITY, Calif.--Nov. 6, 1998--DepoMed, Inc. (Nasdaq:DPMD) announced that
its common stock and warrants (Nasdaq:DPMDW) have been approved for listing on
the American Stock Exchange under the symbols "DMI" and "DMIW," respectively.
The company expects trading to begin on Monday, Nov. 9. The company has selected
Cohen Specialists L.L.C./PALBRO Partners L.L.C. as its specialist unit.
"Our listing on the AMEX is an important milestone for DepoMed," commented John
F. Hamilton, the company's chief financial officer. "The move to the AMEX is
expected to increase corporate visibility, make trading more efficient and
reduce trading costs for our shareholders."
DepoMed, Inc., a development stage company, is engaged in the development of new
and proprietary oral drug delivery technologies. The company has developed two
types of proprietary oral drug delivery systems, the Gastric Retention System,
designed to be retained in the stomach for an extended period of time while it
delivers the incorporated drug or drugs, and the Reduced Irritation System,
designed to reduce gastrointestinal irritation, a side effect of many orally
administered drugs.
Additional information may be found at the company's Web site at
www.depomedinc.com.
The statements in this press release that are not historical facts are forward-
looking statements that involve risk and uncertainties, including risks
identified in the company's registration statement on Form SB-2 (File No. 333-
25445), annual report on Form 10-KSB and other filings with the Securities and
Exchange Commission. Actual results, events, and performance may differ
materially. Readers are cautioned not to place undue relevance on these forward-
looking statements, which speak only as of the date hereof. The company
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statement contained herein to
reflect any change in the company's expectations with regard thereto or any
change in events, conditions or circumstances on which any statements are based.
CONTACT: DepoMed
John F. Hamilton, 650/513-0990 (VP & CFO)
